Nutex Health, Inc. (NUTX) Financial Ratios
16 years of historical data (2010–2025) · Healthcare · Medical - Healthcare Information Services
EV/EBITDA
↑
3.58
-3% vs avg
5yr avg: 3.69
30Y Low3.1·High4.3
P/FCF
↓
3.64
↓-76% vs avg
5yr avg: 15.27
30Y Low4.5·High33.5
P/B Ratio
↓
2.40
↓-36% vs avg
5yr avg: 3.74
30Y Low0.8·High10.0
ROE
↓
22.6%
↓+163% vs avg
5yr avg: -36.1%
30Y Low-272%·High107%
Debt/EBITDA
↑
1.19
↓-20% vs avg
5yr avg: 1.49
30Y Low0.9·High3.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NUTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Nutex Health, Inc. trades at 14.3x earnings, 51% above its 5-year average of 9.5x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 35%. On a free-cash-flow basis, the stock trades at 3.6x P/FCF, 76% below the 5-year average of 15.3x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $894M | $1.1B | $162M | $119M | $1.2B | — | — | — | — | — | — |
| Enterprise Value | $1.1B | $1.3B | $458M | $373M | $1.4B | — | — | — | — | — | — |
| P/E Ratio → | 14.33 | 15.71 | 3.26 | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.02 | 1.27 | 0.34 | 0.48 | 5.50 | — | — | — | — | — | — |
| P/B Ratio | 2.40 | 2.63 | 0.80 | 1.50 | 10.02 | — | — | — | — | — | — |
| P/FCF | 3.64 | 4.53 | 7.75 | — | 33.53 | — | — | — | — | — | — |
| P/OCF | 3.60 | 4.48 | 6.98 | 94.73 | 23.84 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NUTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Nutex Health, Inc.'s enterprise value stands at 3.6x EBITDA, roughly in line with its 5-year average of 3.7x. The Healthcare sector median is 14.2x, placing the stock at a 75% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.46 | 0.95 | 1.51 | 6.56 | — | — | — | — | — | — |
| EV / EBITDA | 3.58 | 4.32 | 3.06 | — | — | — | — | — | — | — | — |
| EV / EBIT | 3.85 | 4.79 | 3.53 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 5.20 | 21.98 | — | 40.01 | — | — | — | — | — | — |
NUTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Nutex Health, Inc. earns an operating margin of 31.5%. Operating margins have expanded from -12.8% to 31.5% over the past 3 years, signaling improving operational efficiency. ROE of 22.6% indicates solid capital efficiency. ROIC of 38.0% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.8% | 50.8% | 40.9% | 14.0% | 7.0% | 54.1% | 57.5% | 100.0% | 31.8% | -952.0% | — |
| Operating Margin | 31.5% | 31.5% | 27.2% | -12.8% | -185.4% | 51.4% | 55.9% | 35.8% | -2003.4% | -10611.8% | — |
| Net Profit Margin | 8.1% | 8.1% | 10.9% | -18.5% | -193.7% | 40.0% | 38.7% | 21.6% | -3080.0% | 1085.0% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.6% | 22.6% | 37.1% | -45.9% | -272.4% | 78.2% | 106.9% | 84.8% | -645.7% | 24.6% | — |
| ROA | 9.0% | 9.0% | 9.9% | -11.0% | -102.8% | 37.7% | 43.4% | 23.3% | -149.0% | 30.3% | -182.4% |
| ROIC | 38.0% | 38.0% | 23.6% | -6.9% | -88.7% | 42.1% | 52.8% | 32.0% | -109.4% | -155.5% | — |
| ROCE | 43.2% | 43.2% | 30.6% | -8.9% | -110.8% | 53.7% | 79.7% | 65.2% | -206.3% | -240.3% | — |
NUTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Nutex Health, Inc. carries a Debt/EBITDA ratio of 1.2x, which is manageable (63% below the sector average of 3.2x). Net debt stands at $166M ($351M total debt minus $186M cash). Interest coverage of 12.0x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.83 | 0.83 | 1.69 | 3.49 | 2.22 | 0.93 | 1.02 | 2.36 | — | 0.16 | — |
| Debt / EBITDA | 1.19 | 1.19 | 2.27 | — | — | 1.00 | 0.94 | 3.23 | — | — | — |
| Net Debt / Equity | — | 0.39 | 1.47 | 3.21 | 1.94 | 0.74 | 0.85 | 2.20 | — | 0.16 | — |
| Net Debt / EBITDA | 0.56 | 0.56 | 1.98 | — | — | 0.80 | 0.78 | 3.01 | — | — | — |
| Debt / FCF | — | 0.68 | 14.23 | — | 6.48 | 1.04 | 4.89 | — | — | — | — |
| Interest Coverage | 12.01 | 12.01 | 6.51 | -1.97 | -32.60 | 28.35 | 23.66 | 10.09 | -1.31 | -15.35 | -173.90 |
NUTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Nutex Health, Inc.'s current ratio of 3.41x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.56x to 3.41x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.41 | 3.41 | 2.08 | 1.56 | 1.79 | 4.09 | 4.31 | 0.63 | 0.29 | 0.06 | 0.08 |
| Quick Ratio | 3.39 | 3.39 | 2.06 | 1.50 | 1.72 | 4.01 | 4.25 | 0.62 | 0.27 | 0.06 | 0.08 |
| Cash Ratio | 1.18 | 1.18 | 0.31 | 0.38 | 0.62 | 0.96 | 0.81 | 0.11 | 0.11 | 0.01 | 0.00 |
| Asset Turnover | — | 0.95 | 0.73 | 0.62 | 0.51 | 0.84 | 0.89 | 0.54 | 0.20 | 0.02 | — |
| Inventory Turnover | 150.38 | 150.38 | 99.55 | 62.78 | 57.70 | 54.10 | 67.46 | — | 2.30 | — | — |
| Days Sales Outstanding | — | 135.71 | 179.52 | 92.52 | 97.06 | 126.34 | 144.04 | 135.91 | 743.60 | 42.55 | — |
NUTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Nutex Health, Inc. returns 0.6% to shareholders annually primarily through share buybacks. The earnings yield of 7.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 4.0% | 4.4% | 4.2% | — | — | — | — | — | — |
| Payout Ratio | — | — | 12.3% | — | — | 108.9% | 55.7% | 90.3% | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 7.0% | 6.4% | 30.6% | — | — | — | — | — | — | — | — |
| FCF Yield | 27.5% | 22.1% | 12.9% | — | 3.0% | — | — | — | — | — | — |
| Buyback Yield | 0.6% | 0.4% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 0.6% | 0.4% | 4.0% | 4.4% | 4.2% | — | — | — | — | — | — |
| Shares Outstanding | — | $7M | $5M | $4M | $4M | $4M | $4M | $4M | $7M | $4M | $2M |
Peer Comparison
Compare NUTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NUTXYou | $894M | 14.3 | 3.6 | 3.6 | 50.8% | 31.5% | 22.6% | 38.0% | 1.2 |
 ADUS | $2B | 18.2 | 12.2 | 17.1 | 32.5% | 9.7% | 9.3% | 8.8% | 1.3 |
 AMSF | $590M | 12.7 | 8.9 | 66.1 | 46.4% | 18.6% | 18.5% | 21.9% | 0.0 |
 UHS | $9B | 6.2 | 5.5 | 10.5 | 90.4% | 11.5% | 21.0% | 12.3% | 2.1 |
 THC | $16B | 11.5 | 6.0 | 6.2 | 82.3% | 16.1% | 16.1% | 13.2% | 3.1 |
 CYH | $428M | 0.8 | — | 2.1 | 8.7% | -79.4% | — | -70.1% | — |
 HCA | $84B | 13.3 | 8.6 | 11.0 | 41.5% | 15.8% | — | 19.9% | 3.2 |
 SGRY | $2B | -23.9 | 10.1 | 9.7 | 23.1% | 11.8% | -2.2% | 4.1% | 7.1 |
 USPH | $952M | 44.0 | 13.1 | 15.6 | 20.1% | 10.3% | 2.0% | 5.6% | 4.1 |
 MCK | $90B | 19.4 | 13.1 | 15.7 | 3.6% | 1.6% | — | 254.1% | 1.2 |
 CAH | $52B | 34.5 | 18.9 | 28.3 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
NUTX — Frequently Asked Questions
Quick answers to the most common questions about buying NUTX stock.
What is Nutex Health, Inc.'s P/E ratio?
Nutex Health, Inc.'s current P/E ratio is 14.3x. The historical average is 9.5x. This places it at the 50th percentile of its historical range.
What is Nutex Health, Inc.'s EV/EBITDA?
Nutex Health, Inc.'s current EV/EBITDA is 3.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 3.7x.
What is Nutex Health, Inc.'s ROE?
Nutex Health, Inc.'s return on equity (ROE) is 22.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 2.5%.
Is NUTX stock overvalued?
Based on historical data, Nutex Health, Inc. is trading at a P/E of 14.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Nutex Health, Inc.'s profit margins?
Nutex Health, Inc. has 50.8% gross margin and 31.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Nutex Health, Inc. have?
Nutex Health, Inc.'s Debt/EBITDA ratio is 1.2x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.